We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marsh & McLennan Companies, Inc. (MMC - Free Report) delivered third-quarter 2019 adjusted earnings per share of 77 cents, surpassing the Zacks Consensus Estimate by 11.6% on the back of solid revenues. However, the same dipped 1.3% year over year.
Marsh & McLennan’s consolidated revenues of $4 billion were up 5% on an underlying basis. This upside is majorly attributable to the Risk and Insurances Services plus Consulting Segments. However, the top line missed the Zacks Consensus Estimate by 0.8%.
Total operating expenses of $3.5 billion in the third quarter were up 18.2% year over year due to higher compensation and benefits as well as other operating expenses.
Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise
Revenues at the Risk and Insurance Services segment were $2.2 billion, up 6% on an underlying basis. Adjusted operating income increased 11% to $313 million from the prior-year quarter’s level.
Marsh, a unit within this segment generated revenues of $1.9 billion, up 5% on an underlying basis. In U.S./Canada, underlying revenues rose 6%.
Underlying revenue growth from international operations of 3% includes 7% increase of the metric in Asia Pacific, 2% rise in the EMEA and a 1% dip in Latin America.
Another unit under this segment, which is Guy Carpenter, displayed 11% revenue growth on an underlying basis.
Consulting
The Consulting segment's revenues improved 4% on an underlying basis to $1.8 billion. Also, adjusted operating income increased 9% year over year to $320 million.
A unit within this segment, Mercer, reported revenues of $1.3 billion, up 3% on an underlying basis. Wealth’s revenues were flat on an underlying basis.
Another unit Oliver Wyman Group registered revenues of $505 million, up 7% on an underlying basis.
Share Repurchase Update
The company bought back shares worth $200 million in the quarter under review.
In the third quarter, the company repaid $300 million of senior notes.
Financial Update
Marsh & McLennan exited the third quarter with cash and cash equivalents of nearly $1.2 billion, up 13.8% from the figure at 2018 end.
Cash flow from operations for the first nine months of 2019 totaled $1.3 billion, down 2.1% year over year.
As of Sep 30, 2019, Marsh & McLennan’s total assets were $31.1 billion, up 44.1% from the figure as of Dec 31, 2018.
Total equity was $7.8 billion, up 2.8% from the level at 2018 end.
Among other players from the insurance industry having reported third-quarter earnings so far, the bottom-line results of The Progressive Corporation (PGR - Free Report) , MGIC Investment Corporation (MTG - Free Report) and RLI Corp. (RLI - Free Report) outpaced the respective Zacks Consensus Estimate.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Marsh & McLennan's (MMC) Q3 Earnings Surpass, Decline Y/Y
Marsh & McLennan Companies, Inc. (MMC - Free Report) delivered third-quarter 2019 adjusted earnings per share of 77 cents, surpassing the Zacks Consensus Estimate by 11.6% on the back of solid revenues. However, the same dipped 1.3% year over year.
Marsh & McLennan’s consolidated revenues of $4 billion were up 5% on an underlying basis. This upside is majorly attributable to the Risk and Insurances Services plus Consulting Segments. However, the top line missed the Zacks Consensus Estimate by 0.8%.
Total operating expenses of $3.5 billion in the third quarter were up 18.2% year over year due to higher compensation and benefits as well as other operating expenses.
Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise
Marsh & McLennan Companies, Inc. price-consensus-eps-surprise-chart | Marsh & McLennan Companies, Inc. Quote
Quarterly Segmental Results
Risk and Insurance Services
Revenues at the Risk and Insurance Services segment were $2.2 billion, up 6% on an underlying basis. Adjusted operating income increased 11% to $313 million from the prior-year quarter’s level.
Marsh, a unit within this segment generated revenues of $1.9 billion, up 5% on an underlying basis. In U.S./Canada, underlying revenues rose 6%.
Underlying revenue growth from international operations of 3% includes 7% increase of the metric in Asia Pacific, 2% rise in the EMEA and a 1% dip in Latin America.
Another unit under this segment, which is Guy Carpenter, displayed 11% revenue growth on an underlying basis.
Consulting
The Consulting segment's revenues improved 4% on an underlying basis to $1.8 billion. Also, adjusted operating income increased 9% year over year to $320 million.
A unit within this segment, Mercer, reported revenues of $1.3 billion, up 3% on an underlying basis. Wealth’s revenues were flat on an underlying basis.
Another unit Oliver Wyman Group registered revenues of $505 million, up 7% on an underlying basis.
Share Repurchase Update
The company bought back shares worth $200 million in the quarter under review.
In the third quarter, the company repaid $300 million of senior notes.
Financial Update
Marsh & McLennan exited the third quarter with cash and cash equivalents of nearly $1.2 billion, up 13.8% from the figure at 2018 end.
Cash flow from operations for the first nine months of 2019 totaled $1.3 billion, down 2.1% year over year.
As of Sep 30, 2019, Marsh & McLennan’s total assets were $31.1 billion, up 44.1% from the figure as of Dec 31, 2018.
Total equity was $7.8 billion, up 2.8% from the level at 2018 end.
Zacks Rank
Marsh & McLennan carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Insurers
Among other players from the insurance industry having reported third-quarter earnings so far, the bottom-line results of The Progressive Corporation (PGR - Free Report) , MGIC Investment Corporation (MTG - Free Report) and RLI Corp. (RLI - Free Report) outpaced the respective Zacks Consensus Estimate.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>